Annexin V, Human Recombinant: Precision Apoptosis Detection Reagent

Executive Summary: Annexin V, human recombinant, is a widely validated, calcium-dependent phosphatidylserine (PS) binding protein used as a sensitive marker of early apoptosis in mammalian cells (Cao et al. 2025). This reagent binds specifically to externalized PS on apoptotic cell membranes, enabling precise distinction from necrotic or healthy cells. The unlabeled format (APExBIO SKU K2064) offers flexibility for conjugation to a variety of detection tags, facilitating applications in flow cytometry, microscopy, and competition assays. Annexin V-based assays underpin both basic research and translational studies in oncology, immunology, and neurodegeneration (Annexin V: Precision Apoptosis Detection Reagent and Mechanistic Tool). Stringent storage (–20°C) and preparation parameters ensure reagent stability and assay reproducibility.

Biological Rationale

Phosphatidylserine is normally restricted to the inner leaflet of the plasma membrane in healthy eukaryotic cells. During early apoptosis, PS is rapidly translocated to the outer leaflet, exposing it to the extracellular environment (Cao et al. 2025). This event is a hallmark of early apoptotic processes and precedes late-stage membrane permeabilization. Annexin V, a 35–36 kDa cellular protein, binds PS with nanomolar affinity in the presence of Ca²⁺ ions (Annexin V as a Next-Generation Apoptosis Assay). The ability to selectively detect PS externalization allows researchers to quantify early-stage apoptosis, distinguish apoptotic from necrotic cells, and investigate mechanisms of cell death relevant to cancer, autoimmunity, and neurodegenerative disease models. The use of human recombinant Annexin V (such as APExBIO’s K2064) ensures batch consistency and low immunogenicity, meeting requirements for sensitive cell-based assays.

Mechanism of Action of Annexin V, human recombinant

Annexin V operates as a calcium-dependent phospholipid-binding protein. Upon addition to cell suspensions or tissue samples, it binds exposed PS on the outer membrane of apoptotic cells. This interaction is strictly Ca²⁺-dependent and reversible upon chelation, ensuring specificity. The following features define its mechanism:

• High Affinity PS Binding: K_d in the nanomolar range in the presence of ≥1.5 mM Ca²⁺ (pH 7.4).
• Competitive Inhibition: Annexin V competes with prothrombin for PS, inhibiting blood coagulation and phospholipase A1 activity (APExBIO product page).
• Conjugation Flexibility: Unlabeled format allows coupling to fluorophores (e.g., FITC, PE) or biotin for diverse detection modalities.
• Reversible Binding: PS-annexin V interaction is lost in the absence of Ca²⁺, allowing for assay controls and wash steps.

This mechanism enables Annexin V, human recombinant, to serve as a sensitive probe for early apoptosis and a tool for dissecting cell death pathways (Annexin V in Apoptosis Assays: Beyond Detection).

Evidence & Benchmarks

• Annexin V detects early apoptotic Jurkat T cells by binding externalized PS, with flow cytometry showing clear separation from live/necrotic populations (Cao et al. 2025).
• The K2064 product is validated for use at 1 µg/mL–5 µg/mL in PBS with 1.5–2.5 mM CaCl₂, showing no signal in cells lacking PS externalization (APExBIO product page).
• Annexin V-based assays are gold-standard for apoptosis quantification in cancer and neurodegenerative disease models, outperforming DNA fragmentation or late-stage viability dyes for early detection (Annexin V: Precision Apoptosis Detection Reagent).
• Competitive binding studies confirm that unlabeled Annexin V can block binding of FITC-Annexin V conjugates, validating specificity and enabling competition assays (Annexin V at the Translational Nexus).
• Lyophilized forms reconstituted to 1–5 mg/mL in PBS (pH 7.4) remain stable for months at –20°C, supporting reproducible multi-assay workflows (APExBIO product page).

Applications, Limits & Misconceptions

Annexin V, human recombinant, is applicable in the following areas:

• Apoptosis Detection: Quantifies early apoptotic cells in mixed populations by PS externalization.
• Flow Cytometry and Microscopy: Conjugation to FITC, PE, or biotin enables multiparametric analysis.
• Cell Death Research: Used in cancer, immunology, and neurodegenerative disease models to study cell fate decisions.
• Blood Coagulation Studies: Investigates PS-dependent coagulation and its inhibition.
• Competition Assays: Unlabeled Annexin V can be used to validate specificity of tagged conjugates.

For more on advanced assay strategies and structural insights, see Annexin V: Structural Insights and Next-Gen Applications—this article updates with new evidence from recombinant formats and workflow integration.

Common Pitfalls or Misconceptions

• Annexin V does not distinguish between apoptotic and necrotic cells unless combined with a secondary viability dye.
• Binding is strictly Ca²⁺-dependent; omission of calcium or use of EDTA/EGTA will result in assay failure.
• It is not suitable for in vivo diagnostic or therapeutic use; research use only (RUO).
• Does not detect late-stage apoptosis where membrane integrity is lost—complement with PI or 7-AAD for full profiling.
• Unlabeled Annexin V requires conjugation to enable detection; it cannot be visualized directly without a tag.

Workflow Integration & Parameters

APExBIO’s Annexin V, human recombinant (SKU K2064), is supplied as a 1 mg/mL liquid in PBS (pH 7.4) and should be stored at –20°C for long-term stability. For lyophilized formats, reconstitute in water or PBS to 1–5 mg/mL. Prior to use, centrifuge the vial briefly to ensure homogeneity. For apoptosis assays:

• Dilute to working concentration (1–5 µg/mL) in PBS with 1.5–2.5 mM CaCl₂.
• Incubate cells for 10–15 minutes at room temperature, protect from light if using conjugates.
• Wash to remove unbound Annexin V; analyze by flow cytometry or fluorescence microscopy.
• For competition assays, pre-incubate cells with unlabeled Annexin V before adding tagged conjugates.
• Maintain all reagents and samples on ice to prevent further apoptosis induction during staining.

Refer to the Annexin V, human recombinant product page for complete instructions and technical support.

Conclusion & Outlook

Annexin V, human recombinant (APExBIO SKU K2064), remains the gold-standard apoptosis detection reagent for research use. Its Ca²⁺-dependent, high-affinity PS binding enables robust, reproducible apoptosis assays across a range of disease models. Ongoing improvements in recombinant protein production and conjugation chemistry are expanding its utility in multiplexed and high-throughput applications. As mechanistic understanding of apoptosis advances, Annexin V-based workflows will continue to anchor cell death research and translational discovery. For expanded mechanistic and assay guidance, see Annexin V at the Translational Nexus, which contextualizes APExBIO’s product in the evolving apoptosis detection landscape.